Search clinical trials for: CPG 7909 continuation study

Total 119405 results

Pfizer

Completed

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Melanoma | Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Lymphoma, T-Cell

United States, Germany
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
University of Iowa
National Cancer Institute (NCI); Mayo Clinic; Pfizer

Completed

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Chronic Lymphocytic Leukemia

United States
Stanford University
National Institutes of Health (NIH)

Withdrawn

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Mycosis Fungoides
Ludwig Institute for Cancer Research

Completed

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Prostate Cancer

Switzerland, Germany
Pfizer

Completed

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Carcinoma, Renal Cell
Pfizer

Completed

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Lymphoma, T-Cell, Cutaneous
Pfizer

Completed

CPG 7909 Injection in Melanoma

Carcinoma, Melanoma
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

Malaria

United States
Wakayama Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

Esophageal Cancer

Japan
National Institute of Allergy and Infectious Diseases...

Terminated

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Bacterial Sepsis

United States
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
University of Aarhus
Aarhus University Hospital

Completed

Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults (ITAP)

HIV Infections

Denmark
Pfizer

Completed

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Carcinoma, Metastatic Breast

United States
Pfizer

Completed

CPG 7909 Injection in Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

United States, Canada, Germany
Ronald Levy
American Society of Clinical Oncology; Lymphoma Research Foundation

Completed

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Mycosis Fungoides | Non-Hodgkin Lymphoma

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

Plasmodium Falciparum Malaria

United States
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909

Malaria

United Kingdom
Azienda Ospedaliera San Camillo Forlanini

Completed

Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients (HCV)

Liver Cirrhosis

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

Malaria

United States, Mali
University of Notre Dame
Infectious Diseases Research Collaboration, Uganda; SC Johnson, A Family Company and other collaborators

Not yet recruiting

Spatial Repellents for Malaria Control (AEGIS Uganda)

Malaria

Uganda
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions

Healthy
University of Adelaide
The First Affiliated Hospital with Nanjing Medical University

Completed

The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes

Type 2 Diabetes

China
Ludwig Institute for Cancer Research

Completed

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

Cancer | Neoplasm

Germany
National Institute of Allergy and Infectious Diseases...
National Institute of Allergy and Infectious Diseases@@@Coley Pharmaceutical...

Completed

Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria

Malaria

Mali
Ahmad Tarhini
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
Masonic Cancer Center, University of Minnesota

Terminated

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Germ Cell Tumor

United States
Universität Duisburg-Essen

Completed

Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy

Quality of Life | Breast Cancer | Chemotherapy | Acupuncture | Mind-Body-Medicine

Germany
Mayo Clinic

Withdrawn

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

Cardiac Disease
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

Malaria

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Emergent BioSolutions
Biomedical Advanced Research and Development Authority

Completed

VELOCITY: An Anthrax Vaccine Clinical Study

Anthrax

United States
National Institute of Allergy and Infectious Diseases...

Completed

Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)

Healthy Volunteer | HV

United States
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria

Malaria

United Kingdom
Ludwig Institute for Cancer Research
NYU Langone Health

Completed

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Tumors

United States
Emergent BioSolutions
Biomedical Advanced Research and Development Authority

Completed

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Anthrax

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Malaria Vaccine for Children in Mali

Malaria | Malaria Infection

Mali
LMU Klinikum

Not yet recruiting

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

Schizophrenia
Biomedical Advanced Research and Development Authority
Rho, Inc.

Completed

BARDA Securing Anthrax Immunity For the Elderly (B-SAFE)

Anthrax

United States
Hassane M. Zarour, MD
National Cancer Institute (NCI)

Completed

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

NY-ESO-1-expressing Tumors

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
Ronald Levy
National Institutes of Health (NIH)

Completed

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Lymphoma, Mantle-Cell

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent... and other conditions

United States
Sanofi

Completed

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

Multiple Sclerosis

United States, Australia, Austria, Bulgaria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Russian Federation, Turkey, Ukraine, United Kingdom
Ionis Pharmaceuticals, Inc.

Not yet recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
Ionis Pharmaceuticals, Inc.

Recruiting

Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

United States
Guy's and St Thomas' NHS Foundation Trust

Recruiting

Continuation Of a Study to Investigate the Effect of Thoracocentesis on Neural Respiratory Drive in Pleural Effusion (COSINE)

Pleural Effusion

United Kingdom

Search clinical trials for: CPG 7909 continuation study

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations